echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > BJH: Can nivolumab alone cure patients with relapsed or refractory Hodgkin lymphoma?

    BJH: Can nivolumab alone cure patients with relapsed or refractory Hodgkin lymphoma?

    • Last Update: 2022-05-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

     Checkpoint blockade with (PD-1) monotherapy has shown promising efficacy in patients with relapsed/refractory Hodgkin lymphoma (R/R HL)


     Checkpoint blockade with (PD-1) monotherapy has shown promising efficacy in patients with relapsed/refractory Hodgkin lymphoma (R/R HL)


    It has been suggested that younger patients with early and deep responses are more likely to be relapse-free 1 year after anti-PD-1 discontinuation


    Here, we report a 5-year analysis of the ATU-nivo study, a retrospective nationwide study visit program in R/R HL patients ≥18 years of age who received nivolumab early in France ( EAP)


    Seventy-six patients were included in the efficacy analysis


    To assess whether some patients could be cured with nivolumab alone as systemic therapy, the research team analyzed 19 patients who achieved a CR without consolidation therapy (5 patients had concomitant radiation therapy)


    After a median follow-up of 5.


    Nivolumab 1

    Figure 1: Progression-free survival (PFS; blue) and overall survival (OS; red) in patients with complete remission (CR) on nivolumab monotherapy without concomitant/consolidation therapy (radiation allowed)

    Figure 1: Progression-free survival (PFS; blue) and overall survival (OS; red) in patients with complete remission (CR) on nivolumab monotherapy without concomitant/consolidation therapy (radiation allowed) Figure 1: Progression-free survival (PFS; blue) and overall survival (OS; red) in patients with complete remission (CR) on nivolumab monotherapy without concomitant/consolidation therapy (radiation allowed)

    Nine patients relapsed, six of whom received salvage therapy: three received a second course of anti-PD-1, and three received radiotherapy and/or chemotherapy


    Nivolumab

    In total, two patients died: one from metastatic colorectal cancer (6 months after initiation of nivolumab) and one from coronavirus disease 2019 (COVID-19)


    n

    Overall, this was the longest follow-up reported in this setting


    n

    In conclusion, this study confirms that, after long-term follow-up, nivolumab is an effective strategy in this heavily pretreated population


    After long-term follow-up, nivolumab was an effective strategy in this heavily pretreated population


    Original source:

    Original source:

    Manson, G.


    Manson, G.
    , Herbaux, C.
    , Schiano, J.
    -M.
    , Casasnovas, O.
    , Stamatoullas, A.
    , Deau, B.
    , Schmitt, A.
    , Regny, C.
    , Bouabdallah, K.
    , Chauchet, A.
    , Ghesquieres, H.
    , Tempescul, A.
    , Dulery, R.
    , Nicolas-Virelizier, E.
    , Delmer, A.
    , Borel, C.
    , Dercle, L.
    , Brice, P.
    , Houot, R.
    and (2022), Can nivolumab alone cure patients with relapse or refractory Hodgkin lymphoma? A 5-year analysis of the French early access program (EPA).
    Br J Haematol.
    https://doi.
    org/10.
    1111/bjh.
    18198Manson, G.
    , Herbaux, C.
    , Schiano, J.
    -M.
    , Casasnovas, O.
    , Stamatoullas, A.
    , Deau, B.
    , Schmitt, A.
    , Regny, C.
    , Bouabdallah, K.
    , Chauchet, A.
    , Ghesquieres, H.
    , Tempescul, A.
    , Dulery, R.
    , Nicolas-Virelizier, E.
    , Delmer, A.
    , Borel, C.
    , Dercle, L.
    , Brice, P.
    , Houot, R.
    and (2022), Can nivolumab alone cure patients with relapse or refractory Hodgkin lymphoma? A 5-year analysis of the French early access program (EPA).
    Br J Haematol.
    https://doi.
    org/10.
    1111/bjh.
    18198

    here message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.